BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23149818)

  • 1. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.
    Perna SK; De Angelis B; Pagliara D; Hasan ST; Zhang L; Mahendravada A; Heslop HE; Brenner MK; Rooney CM; Dotti G; Savoldo B
    Clin Cancer Res; 2013 Jan; 19(1):106-17. PubMed ID: 23149818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.
    Perna SK; Pagliara D; Mahendravada A; Liu H; Brenner MK; Savoldo B; Dotti G
    Clin Cancer Res; 2014 Jan; 20(1):131-9. PubMed ID: 24097874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
    Savoldo B; Rooney CM; Di Stasi A; Abken H; Hombach A; Foster AE; Zhang L; Heslop HE; Brenner MK; Dotti G
    Blood; 2007 Oct; 110(7):2620-30. PubMed ID: 17507664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.
    Roskrow MA; Suzuki N; Gan Yj; Sixbey JW; Ng CY; Kimbrough S; Hudson M; Brenner MK; Heslop HE; Rooney CM
    Blood; 1998 Apr; 91(8):2925-34. PubMed ID: 9531603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
    Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
    Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma.
    Wheatley GH; McKinnon KP; Iacobucci M; Mahon S; Gelber C; Lyerly HK
    Surgery; 1998 Aug; 124(2):171-6. PubMed ID: 9706135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.
    Quintarelli C; Vera JF; Savoldo B; Giordano Attianese GM; Pule M; Foster AE; Heslop HE; Rooney CM; Brenner MK; Dotti G
    Blood; 2007 Oct; 110(8):2793-802. PubMed ID: 17638856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EBV-related lymphomas: new approaches to treatment.
    Kanakry JA; Ambinder RF
    Curr Treat Options Oncol; 2013 Jun; 14(2):224-36. PubMed ID: 23549980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory T cells and EBV associated malignancies.
    Li J; Qian CN; Zeng YX
    Int Immunopharmacol; 2009 May; 9(5):590-2. PubMed ID: 19539572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
    Bollard CM; Aguilar L; Straathof KC; Gahn B; Huls MH; Rousseau A; Sixbey J; Gresik MV; Carrum G; Hudson M; Dilloo D; Gee A; Brenner MK; Rooney CM; Heslop HE
    J Exp Med; 2004 Dec; 200(12):1623-33. PubMed ID: 15611290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture.
    Sharif-Askari E; Fawaz LM; Tran P; Ahmad A; Menezes J
    J Natl Cancer Inst; 2001 Nov; 93(22):1724-32. PubMed ID: 11717333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
    Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
    Sun Q; Burton R; Reddy V; Lucas KG
    Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.
    Ricciardelli I; Blundell MP; Brewin J; Thrasher A; Pule M; Amrolia PJ
    Blood; 2014 Oct; 124(16):2514-22. PubMed ID: 25185261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy to improve function of T cells for adoptive immunotherapy.
    Quintarelli C; Savoldo B; Dotti G
    Methods Mol Biol; 2010; 651():119-30. PubMed ID: 20686964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients.
    Savoldo B; Goss J; Liu Z; Huls MH; Doster S; Gee AP; Brenner MK; Heslop HE; Rooney CM
    Transplantation; 2001 Sep; 72(6):1078-86. PubMed ID: 11579304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.
    Gerdemann U; Katari U; Christin AS; Cruz CR; Tripic T; Rousseau A; Gottschalk SM; Savoldo B; Vera JF; Heslop HE; Brenner MK; Bollard CM; Rooney CM; Leen AM
    Mol Ther; 2011 Dec; 19(12):2258-68. PubMed ID: 21915103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.
    Dotti G; Savoldo B; Pule M; Straathof KC; Biagi E; Yvon E; Vigouroux S; Brenner MK; Rooney CM
    Blood; 2005 Jun; 105(12):4677-84. PubMed ID: 15713795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
    Wagner HJ; Bollard CM; Vigouroux S; Huls MH; Anderson R; Prentice HG; Brenner MK; Heslop HE; Rooney CM
    Cancer Gene Ther; 2004 Feb; 11(2):81-91. PubMed ID: 14685154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.